Skip to main content

Table 3 Comparison of test performance of Aptima and the TaqPath using non-diluted clinical samples

From: Assessment of the clinical and analytical performance of the Aptima SARS-CoV-2 assay using the VALCOR protocol

  

TaqPath

  
  

Positive

Negative

Total

Aptima SARS- CoV-2

Positive

88

3*

91

 

Negative

0

89

81

 

Total

88

92

180

Sensitivity

100.0%

(95% CI 95.9–100.0)

Specificity

96.7%

(95% CI 90.8–99.3)

Overall agreement

98.3%

(95% CI 95.2–99.7)

Cohen’s Kappa (k) (95% CI)

0.967

(95% CI 0.929–1.000)

  1. *Only two of three Aptima positive/TaqPath negative samples were confirmed discordant
Back to article page

Virology Journal

ISSN: 1743-422X